Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design and Data Collection
2.2. Literature Review
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hodi, F.S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Rutkowski, P.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018, 19, 1480–1492. [Google Scholar] [CrossRef] [PubMed]
- Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372, 2018–2028. [Google Scholar] [CrossRef] [PubMed]
- Mehra, R.; Seiwert, T.Y.; Gupta, S.; Weiss, J.; Gluck, I.; Eder, J.P.; Burtness, B.; Tahara, M.; Keam, B.; Kang, H.; et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012. Br. J. Cancer 2018, 119, 153–159. [Google Scholar] [CrossRef]
- Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.; Plimack, E.R.; et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2015, 373, 1803–1813. [Google Scholar] [CrossRef] [PubMed]
- Tarhini, A.A. The current state of adjuvant therapy of melanoma. Lancet Oncol. 2020, 21, 1394–1395. [Google Scholar] [CrossRef] [PubMed]
- Hargadon, K.M.; Johnson, C.E.; Williams, C.J. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 2018, 62, 29–39. [Google Scholar] [CrossRef] [PubMed]
- Postow, M.A.; Sidlow, R.; Hellmann, M.D. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N. Engl. J. Med. 2018, 378, 158–168. [Google Scholar] [CrossRef] [PubMed]
- Cabanie, C.; Ammari, S.; Hans, S.; Pobel, C.; Laparra, A.; Danlos, F.X.; Chanson, N.; Dolidon, S.; Seban, R.; Voisin, A.-L.; et al. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. Eur. J. Cancer 2021, 156, 46–59. [Google Scholar] [CrossRef]
- Rambhia, P.H.; Reichert, B.; Scott, J.F.; Feneran, A.N.; Kazakov, J.A.; Honda, K.; Chanson, N.; Dolidon, S.; Seban, R.; Voisin, A.-L. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. Int. J. Clin. Oncol. 2019, 24, 1171–1181. [Google Scholar] [CrossRef] [PubMed]
- Mortaz, E.; Rezayat, F.; Amani, D.; Kiani, A.; Garssen, J.; Adcock, I.M.; Velayati, A. The Roles of T Helper 1, T Helper 17 and Regulatory T Cells in the Pathogenesis of Sarcoidosis. Iran. J. Allergy Asthma Immunol. 2016, 15, 334–339. [Google Scholar]
- von Euw, E.; Chodon, T.; Attar, N.; Jalil, J.; Koya, R.C.; Comin-Anduix, B.; Ribas, A. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J. Transl. Med. 2009, 7, 35. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Liu, Z.; Tian, M.; Hu, X.; Wang, L.; Ji, J.; Liao, A. The altered PD-1/PD-L1 pathway delivers the ‘one-two punch’ effects to promote the Treg/Th17 imbalance in pre-eclampsia. Cell. Mol. Immunol. 2018, 15, 710–723. [Google Scholar] [CrossRef]
- D’Addio, F.; Riella, L.V.; Mfarrej, B.G.; Chabtini, L.; Adams, L.T.; Yeung, M.; Yagita, H.; Azuma, M.; Sayegh, M.H.; Guleria, I. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J. Immunol. 2011, 187, 4530–4541. [Google Scholar] [CrossRef] [PubMed]
- McAlees, J.W.; Lajoie, S.; Dienger, K.; Sproles, A.A.; Richgels, P.K.; Yang, Y.; Khodoun, M.; Azuma, M.; Yagita, H.; Fulkerson, P.C.; et al. Differential control of CD4+ T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. Eur. J. Immunol. 2015, 45, 1019–1029. [Google Scholar] [CrossRef]
- Tarhini, A.A.; Lee, S.J.; Hodi, F.S.; Rao, U.N.M.; Cohen, G.I.; Hamid, O.; Hutchins, L.F.; Sosman, J.A.; Kluger, H.M.; Eroglu, Z.; et al. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J. Clin. Oncol. 2020, 38, 567–575. [Google Scholar] [CrossRef]
- Grossmann, K.F.; Othus, M.; Patel, S.P.; Tarhini, A.A.; Sondak, V.K.; Knopp, M.V.; Petrella, T.M.; Truong, T.-G.; Khushalani, N.I.; Cohen, J.V.; et al. Adjuvant Pembrolizumab versus IFNalpha2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022, 12, 644–653. [Google Scholar] [CrossRef] [PubMed]
- Danlos, F.X.; Pages, C.; Baroudjian, B.; Vercellino, L.; Battistella, M.; Mimoun, M.; Jebali, M.; Bagot, M.; Tazi, A.; Lebbé, C. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient with Advanced Melanoma. Chest 2016, 149, e133–e136. [Google Scholar] [CrossRef]
- Timmermans, W.M.; van Laar, J.A.; van Hagen, P.M.; van Zelm, M.C. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin. Transl. Immunol. 2016, 5, e118. [Google Scholar] [CrossRef]
- Beutler, B.D.; Cohen, P.R. Sarcoidosis in Melanoma Patients: Case Report and Literature Review. Cancers 2015, 7, 1005–1021. [Google Scholar] [CrossRef]
- Melin, A.; Routier, E.; Roy, S.; Pradere, P.; Le Pavec, J.; Pierre, T.; Chanson, N.; Scoazec, J.-Y.; Lambotte, O.; Robert, C. Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma. Cancers 2022, 14, 2937. [Google Scholar] [CrossRef]
- Cornejo, C.M.; Haun, P.; English, J., 3rd; Rosenbach, M. Immune checkpoint inhibitors and the development of granulomatous reactions. J. Am. Acad. Dermatol. 2019, 81, 1165–1175. [Google Scholar] [CrossRef] [PubMed]
- Ravenel, J.G.; McAdams, H.P.; Plankeel, J.F.; Butnor, K.J.; Sporn, T.A. Sarcoidosis induced by interferon therapy. AJR Am. J. Roentgenol. 2001, 177, 199–201. [Google Scholar] [CrossRef]
- Criado, E.; Sanchez, M.; Ramirez, J.; Arguis, P.; de Caralt, T.M.; Perea, R.J.; Xaubet, A. Pulmonary sarcoidosis: Typical and atypical manifestations at high-resolution CT with pathologic correlation. Radiographics 2010, 30, 1567–1586. [Google Scholar] [CrossRef]
- Ung, C.; Gragoudas, E. Checkpoint inhibitor-induced sarcoid choroidal granulomas. Am. J. Ophthalmol. Case Rep. 2020, 18, 100652. [Google Scholar] [CrossRef]
- Kubo, T.; Hirohashi, Y.; Keira, Y.; Akimoto, M.; Ikeda, T.; Kikuchi, N.; Iwaki, H.; Kikuchi, T.; Obata, M.; Morita, R.; et al. Identification of characteristic subepithelial surface granulomatosis in immune-related adverse event-associated enterocolitis. Cancer Sci. 2021, 112, 1320–1325. [Google Scholar] [CrossRef] [PubMed]
- Andersen, R.; Norgaard, P.; Al-Jailawi, M.K.; Svane, I.M. Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology 2014, 3, e954506. [Google Scholar] [CrossRef] [PubMed]
- Apalla, Z.; Kemanetzi, C.; Papageorgiou, C.; Bobos, M.; Manoli, M.; Fotiadou, C.; Hatzibougias, D.; Boukovinas, I.; Stergiou, E.; Levva, S.; et al. Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case. Dermatol. Ther. 2021, 34, e14618. [Google Scholar] [CrossRef]
- Lomax, A.J.; McGuire, H.M.; McNeil, C.; Choi, C.J.; Hersey, P.; Karikios, D.; Shannon, K.; van Hal, S.; Carr, U.; Crotty, A.; et al. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis. Int. J. Rheum. Dis. 2017, 20, 1277–1285. [Google Scholar] [CrossRef]
- Tarhini, A.A.; Zahoor, H.; Lin, Y.; Malhotra, U.; Sander, C.; Butterfield, L.H.; Kirkwood, J.M. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 2015, 3, 39. [Google Scholar] [CrossRef]
- Tetzlaff, M.T.; Nelson, K.C.; Diab, A.; Staerkel, G.A.; Nagarajan, P.; Torres-Cabala, C.A.; Chasen, B.A.; Wargo, J.A.; Prieto, V.G.; Amaria, R.N.; et al. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: A marker of therapy response in a subset of melanoma patients. J. Immunother. Cancer 2018, 6, 14. [Google Scholar] [CrossRef]
- Tarhini, A.A.; Kirkwood, J.M. Clinical and immunologic basis of interferon therapy in melanoma. Ann. N. Y. Acad. Sci. 2009, 1182, 47–57. [Google Scholar] [CrossRef]
- Massaguer, S.; Sanchez, M.; Castel, T. Mediastinal sarcoidosis induced by high-dose alpha-2-interferon therapy in a patient with malignant melanoma. Eur. Radiol. 2004, 14, 1716–1717. [Google Scholar] [CrossRef] [PubMed]
- Pietropaoli, A.; Modrak, J.; Utell, M. Interferon-alpha therapy associated with the development of sarcoidosis. Chest 1999, 116, 569–572. [Google Scholar] [CrossRef] [PubMed]
- Puzanov, I.; Diab, A.; Abdallah, K.; Bingham, C.O., 3rd; Brogdon, C.; Dadu, R.; Hamad, L.; Kim, S.; Lacouture, M.E.; Le Boeuf, N.R.; et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 2017, 5, 95. [Google Scholar] [CrossRef]
- Dimitriou, F.; Frauchiger, A.L.; Urosevic-Maiwald, M.; Naegeli, M.C.; Goldinger, S.M.; Barysch, M.; Franzen, D.; Kamarachev, J.; Braun, R.; Dummer, R.; et al. Sar-coid-like reactions in patients receiving modern melanoma treatment. Melanoma Res. 2018, 28, 230–236. [Google Scholar] [CrossRef] [PubMed]
- Le Burel, S.; Champiat, S.; Mateus, C.; Marabelle, A.; Michot, J.M.; Robert, C.; Belkhir, R.; Soria, J.C.; Laghouati, S.; Voisin, A.L.; et al. Prevalence of im-mune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur. J. Cancer. 2017, 82, 34–44. [Google Scholar] [CrossRef] [PubMed]
- Reddy, S.B.; Possick, J.D.; Kluger, H.M.; Galan, A.; Han, D. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma. J. Immunother. 2017, 40, 307–311. [Google Scholar] [CrossRef]
- Toumeh, A.; Sakhi, R.; Shah, S.; Arudra, S.K.; De Las Casas, L.E.; Skeel, R.T. Ipilimumab-Induced Granuloma-tous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melano-ma. Am. J. Ther. 2016, 23, e1068–e1071. [Google Scholar] [CrossRef] [PubMed]
- Yatim, N.; Mateus, C.; Charles, P. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission. Rev. Méd. Interne 2018, 39, 130–133. [Google Scholar] [CrossRef]
- Firwana, B.; Ravilla, R.; Raval, M.; Hutchins, L.; Mahmoud, F. Sarcoidosis-like syndrome and lymphade-nopathy due to checkpoint inhibitors. J. Oncol. Pharm. Pract. 2017, 23, 620–624. [Google Scholar] [CrossRef]
- Leboráns, L.M.; Martínez, A.E.; Martínez, A.V.; de Miquel, V.A.; Jaime, A.B. Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy. Dermatol. Ther. 2016, 29, 306–308. [Google Scholar] [CrossRef]
- Tissot, C.; Carsin, A.; Freymond, N.; Pacheco, Y.; Devouassoux, G.; Naeije, R.; Chemla, D.; Dinh-Xuan, A.T.; Noordegraaf, A.V. Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. Eur. Respir. J. 2012, 41, 246–247. [Google Scholar] [CrossRef]
- Eckert, A.; Schoeffler, A.; Dalle, S.; Phan, A.; Kiakouama, L.; Thomas, L. Anti-CTLA4 monoclonal antibody in-duced sarcoidosis in a metastatic melanoma patient. Dermatology 2009, 218, 69–70. [Google Scholar] [CrossRef]
- Seve, P.; Schott, A.M.; Pavic, M.; Broussolle, C.; Gilis, L.; Thomas, L. Sarcoidosis and Melanoma: A Referral Center Study of 1,199 Cases. Dermatology 2009, 219, 25–31. [Google Scholar] [CrossRef] [PubMed]
- Reule, R.B.; North, J.P. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipili-mumab. J. Am. Acad. Dermatol. 2013, 69, e272–e273. [Google Scholar] [CrossRef] [PubMed]
- McKenna, M.C.; Molloy, K.; Crowther, S.; Feeney, J.; Gillis, A.; Connolly, M.; Kelleher, F. Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars. J. Oncol. Pr. 2018, 14, 200–201. [Google Scholar] [CrossRef] [PubMed]
- Jespersen, H.; Bjursten, S.; Ny, L.; Levin, M. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. Lancet Oncol. 2018, 19, e327. [Google Scholar] [CrossRef] [PubMed]
- Burillo-Martinez, S.; Morales-Raya, C.; Prieto-Barrios, M.; Rodriguez-Peralto, J.L.; Ortiz-Romero, P.L. Pem-brolizumab-Induced Extensive Panniculitis and Nevus Regression: Two Novel Cutaneous Manifestations of the Post-immunotherapy Granulomatous Reactions Spectrum. JAMA Dermatol. 2017, 153, 721–722. [Google Scholar] [CrossRef]
- Balestra, R.; Benzaquen, S.; Wang, J. Sarcoidosis-like Granulomatous Lung Reaction Associated with Anti–Programmed Death Receptor-1 Ligand Therapy. Ann. Am. Thorac. Soc. 2017, 14, 296–299. [Google Scholar] [CrossRef]
- Cheshire, S.C.; Board, R.E.; Lewis, A.R.; Gudur, L.D.; Dobson, M.J. Pembrolizumab-induced Sarcoid-like Reac-tions during Treatment of Metastatic Melanoma. Radiology 2018, 289, 564–567. [Google Scholar] [CrossRef]
- Wesselius, L.J.; DeLeon, T.T.; Gotway, M.B. A Sarcoidlike Reaction Mimicking Metastatic Malignancy in a Patient With Melanoma Treated With Pembrolizumab. Am. J. Roentgenol. 2018, 210, W183–W184. [Google Scholar] [CrossRef]
- Gutzmer, R.; Koop, A.; Meier, F.; Hassel, J.C.; Terheyden, P.; Zimmer, L. Programmed cell death pro-tein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur. J. Cancer. 2017, 75, 24–32. [Google Scholar] [CrossRef] [PubMed]
- Lidar, M.; Giat, E.; Garelick, D.; Horowitz, Y.; Amital, H.; Steinberg-Silman, Y. Rheumatic manifesta-tions among cancer patients treated with immune checkpoint inhibitors. Autoimmun. Rev. 2018, 17, 284–289. [Google Scholar] [CrossRef]
- Al-Dliw, M.; Megri, M.; Shahoub, I.; Sahay, G.; Limjoco, T.I.; Shweihat, Y. Pembrolizumab reactivates pul-monary granulomatosis. Respir. Med. Case Rep. 2017, 22, 126–129. [Google Scholar] [PubMed]
- Nandavaram, S.; Nadkarni, A. Ipilimumab-Induced Sarcoidosis and Thyroiditis. Am. J. Ther. 2018, 25, e379–e380. [Google Scholar] [CrossRef] [PubMed]
- Wilgenhof, S.; Morlion, V.; Seghers, A.C.; Du Four, S.; Vanderlinden, E.; Hanon, S. Sarcoidosis in a pa-tient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selec-tive BRAF inhibitor. Anticancer. Res. 2012, 32, 1355–1359. [Google Scholar]
- Murphy, K.P.; Kennedy, M.P.; Barry, J.E.; O’Regan, K.N.; Power, D.G. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal an-tibody treatment. Oncol. Res. Treat. 2014, 37, 351–353. [Google Scholar] [CrossRef]
- Berthod, G.; Lazor, R.; Letovanec, I.; Romano, E.; Noirez, L.; Mazza-Stalder, J.; Speiser, D.; Peters, S.; Michielin, O. Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab. J. Clin. Oncol. 2012, 30, e156–e159. [Google Scholar] [CrossRef] [PubMed]
- Vogel, W.V.; Guislain, A.; Kvistborg, P.; Schumacher, T.N.; Haanen, J.B.; Blank, C.U. Ipilimumab-induced sar-coidosis in a patient with metastatic melanoma undergoing complete remission. J. Clin. Oncol. 2012, 30, e7–e10. [Google Scholar] [CrossRef]
- Montaudie, H.; Pradelli, J.; Passeron, T.; Lacour, J.P.; Leroy, S. Pulmonary sarcoid-like granulomatosis in-duced by nivolumab. Br. J. Dermatol. 2017, 176, 1060–1063. [Google Scholar] [CrossRef]
- Koelzer, V.H.; Rothschild, S.I.; Zihler, D.; Wicki, A.; Willi, B.; Willi, N. Systemic inflammation in a mela-noma patient treated with immune checkpoint inhibitors-an autopsy study. J. Immunother. Cancer. 2016, 4, 13. [Google Scholar] [CrossRef]
- Bronstein, Y.; Ng, C.S.; Hwu, P.; Hwu, W.-J. Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody Therapy. Am. J. Roentgenol. 2011, 197, W992–W1000. [Google Scholar] [CrossRef] [PubMed]
- Gilardi, L.; Colandrea, M.; Vassallo, S.; Travaini, L.L.; Paganelli, G. Ipilimumab-induced immunomediated adverse events: Possible pitfalls in (18)F-FDG PET/CT interpretation. Clin. Nucl. Med. 2014, 39, 472–474. [Google Scholar] [CrossRef] [PubMed]
- Arellano, K.; Mosley, J.C.; Moore, D.C. Case Report of Ipilimumab-Induced Diffuse, Nonnecrotizing Granulomatous Lymphadenitis and Granulomatous Vasculitis. J. Pharm. Pract. 2018, 31, 227–229. [Google Scholar] [CrossRef]
- Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366, 2455–2465. [Google Scholar] [CrossRef] [PubMed]
- Jiang, B.; Patino, M.M.; Gross, A.J.; Leong, S.P.L.; Moretto, J.C.; Kashani-Sabet, M. Diffuse granuloma-tous panniculitis associated with anti PD-1 antibody therapy. JAAD Case Rep. 2018, 4, 13–16. [Google Scholar] [CrossRef] [PubMed]
- Tetzlaff, M.T.; Jazaeri, A.A.; Torres-Cabala, C.A.; Korivi, B.R.; Landon, G.A.; Nagarajan, P.; Choksi, A.; Chen, L.; Uemura, M.; Aung, P.P.; et al. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J. Cutan. Pathol. 2017, 44, 1080–1086. [Google Scholar] [CrossRef]
- Wu, J.; Kwong, B.; Martires, K.; Rieger, K.; Hung, S.-I.; Iyer, G.; Lacouture, M. Granuloma annulare associated with immune checkpoint inhibitors. J. Eur. Acad. Dermatol. Venereol. 2017, 32, e124–e126. [Google Scholar] [CrossRef]
- Kubicki, S.L.; Welborn, M.E.; Garg, N.; Aung, P.; Patel, A.B. Granulomatous dermatitis associated with ipilimumab therapy (ipilimumab associated granulomatous dermatitis). J. Cutan. Pathol. 2018, 45, 636–638. [Google Scholar] [CrossRef]
- Perret, R.E.; Josselin, N.; Knol, A.-C.; Khammari, A.; Cassecuel, J.; Peuvrel, L.; Dreno, B. Supported by GESTIM Nantes group of cutaneous adverse events induced by anticancer drugs Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma. Int. J. Dermatol. 2017, 56, 527–533. [Google Scholar] [CrossRef]
- Diaz-Perez, J.A.; Beveridge, M.G.; Victor, T.A.; Cibull, T.L. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer. J. Cutan. Pathol. 2018, 45, 434–438. [Google Scholar] [CrossRef]
- Chorti, E.; Kanaki, T.; Zimmer, L.; Hadaschik, E.; Ugurel, S.; Gratsias, E.; Roesch, A.; Bonella, F.; Wessendorf, T.E.; Wälscher, J.; et al. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. Eur. J. Cancer 2020, 131, 18–26. [Google Scholar] [CrossRef] [PubMed]
- Mobini, N.; Dhillon, R.; Dickey, J.; Spoon, J.; Sadrolashrafi, K. Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of Two Cases with Unusual Manifestations and Review of the Literature. Case Rep. Dermatol. Med. 2019, 2019, 6702870. [Google Scholar] [CrossRef]
- Reuss, J.E.; Kunk, P.R.; Stowman, A.M.; Gru, A.A.; Slingluff, C.L.; Gaughan, E.M. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: A case report & review of the literature. J. Immunother. Cancer 2016, 4, 94. [Google Scholar] [CrossRef]
- Rodriguez, E.F.; Lipson, E.; Suresh, K.; Cappelli, L.C.; Monaco, S.E.; Maleki, Z. Immune checkpoint block-er-related sarcoid-like granulomatous inflammation: A rare adverse event detected in lymph node aspi-ration cytology of patients treated for advanced malignant melanoma. Hum. Pathol. 2019, 91, 69–76. [Google Scholar] [CrossRef] [PubMed]
- Laroche, A.; Alarcon, C.E.; Bourgeault, E.; Dore, M.A. Erythema Nodosum as the Initial Presen-tation of Nivolumab-Induced Sarcoidosis-Like Reaction. J. Cutan. Med. Surg. 2018, 22, 627–629. [Google Scholar] [CrossRef]
- Tan, I.; Malinzak, M.; Salama, A.K.S. Delayed onset of neurosarcoidosis after concurrent ipili-mumab/nivolumab therapy. J. Immunother. Cancer. 2018, 6, 77. [Google Scholar] [CrossRef] [PubMed]
- Dunn-Pirio, A.M.; Shah, S.; Eckstein, C. Neurosarcoidosis following Immune Checkpoint Inhibition. Case Rep. Oncol. 2018, 11, 521–526. [Google Scholar] [CrossRef]
- Tulbah, R.I.; Rowe, S.P.; Solnes, L.B.; Javadi, M.S. Nivolumab-Associated Pulmonary and Bone Sarcoidosis in a Patient With Melanoma of Unknown Primary. Clin. Nucl. Med. 2019, 44, e519–e521. [Google Scholar] [CrossRef]
- Fukuchi, K.; Hikawa, M.; Sano, Y.; Kasuya, A.; Aoshima, M.; Tatsuno, K. Sarcoid-like reaction and viti-ligo occurring after nivolumab therapy in a patient with metastatic melanoma. J. Dermatol. 2019, 46, e359–e360. [Google Scholar] [CrossRef]
- Lise, Q.-K.; Audrey, A.-G. Multifocal choroiditis as the first sign of systemic sarcoidosis associated with pembrolizumab. Am. J. Ophthalmol. Case Rep. 2016, 5, 92–93. [Google Scholar] [CrossRef]
- Nishino, M.; Sholl, L.M.; Awad, M.M.; Hatabu, H.; Armand, P.; Hodi, F.S. Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Im-mune-Related Adverse Event. Cancer Immunol. Res. 2018, 6, 630–635. [Google Scholar] [CrossRef] [PubMed]
- Smith, R.J.; Mitchell, T.C.; Chu, E.Y. Pembrolizumab-induced sarcoidal infusion site reaction. J. Cutan. Pathol. 2018, 45, 727–729. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Patel, G.; Chiesa-Fuxench, Z.C.; Mcgettigan, S.; Schuchter, L.; Mitchell, T.C.; Ming, M.E.; Chu, E.Y. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy. JAMA Dermatol. 2018, 154, 1057–1061. [Google Scholar] [CrossRef]
- Woodbeck, R.; Metelitsa, A.I.; Naert, K.A. Granulomatous Tumoral Melanosis Associated With Pembroli-zumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma. Am. J. Dermatopathol. 2018, 40, 523–526. [Google Scholar] [CrossRef]
- Lu, Y. FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis. Clin. Nucl. Med. 2019, 44, 167–168. [Google Scholar] [CrossRef] [PubMed]
- Marcoval, J.; Bauer-Alonso, A.; Fornons-Servent, R.; Jiménez-Colomo, L.; Sabaté-Llobera, A.; Penín, R. Subcutaneous sarcoidosis induced by pembrolizumab in a melanoma patient mimicking subcutaneous metastasis at 18F-FDG PET/CT. Rev. Esp. Med. Nucl. Imagen Mol. (Engl. Ed.) 2020, 40, 255–256. [Google Scholar] [CrossRef]
- Garanzini, E.M.; Scaramuzza, D.; Spadarella, G.; Di Guardo, L.; Marchianò, A. Sarcoidosis-like disease mimicking metastases during adjuvant ipilimumab therapy in advanced melanoma patient: CT scan and MRI help in managing difficult clinical decision. BJR|Case Rep. 2020, 6, 20190065. [Google Scholar] [CrossRef] [PubMed]
- Cervantes, J.; Rosen, A.; Dehesa, L.; Dickinson, G.; Alonso-Llamazares, J. Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cuta-neous Findings. Actas Dermosifiliogr. (Engl. Ed). 2019, 110, 43–49. [Google Scholar] [CrossRef]
- Yasin, H.; Yadala, V.; Khan, N.A.J.; Graffeo, V.; Denning, K.; Lebowicz, Y. Immunotherapy-Induced Sar-coid-Like Reaction: A Shrewd Imitator. J. Investig. Med. High Impact Case Rep. 2021, 9, 23247096211009400. [Google Scholar] [PubMed]
Clinical Trial | Organ(s) Involved | Ipi3 (n = 523) | Ipi10 (n = 932) | Total Ipi (n = 1455) | HDI (n = 783) | Pembrolizumab (n = 640) |
---|---|---|---|---|---|---|
ECOG-ACRIN E1609 | Ocular | 0 | 1 (Gr 2) | 1 | 0 | NA |
Skin | 0 | 1 (Gr 1) | 1 | 0 | NA | |
Lung and Lymphatic | 1 (Gr 3) | 2 (Gr 3) | 3 | 1 (Gr 3) | NA | |
SWOG S1404 | Skin | NA | 1 (Gr 1) | 1 | 0 | 0 |
Lymphatic | NA | 0 | 0 | 0 | 1 (Gr 1) | |
Lung and Lymphatic | NA | 1 (Gr 2) | 1 | 0 | 2 (Gr 1, Gr 3) | |
Total, n (%) 95% C.I | 1 (0.19%) 0.003–1.08% | 6 (0.64%) 0.3–1.4% | 7 (0.48%) 0.23–0.99% | 1 (0.13%) 0.02–0.72%) | 3 (0.47%) 0.16–1.37% |
Organ Involved * | Immune Checkpoint Inhibitor | ||
---|---|---|---|
PD1 | CTLA4 | PD1 + CTLA4 | |
Cutaneous, no. | 25 | 13 | 10 |
Pulmonary, no. | 23 | 21 | 3 |
Lymphatic, no. | 26 | 23 | 11 |
Ocular, no. | 4 | 0 | 0 |
Neurologic, no. | 0 | 1 | 2 |
Other visceral, non-visceral, no. | 2 ¥ | 4 # | 0 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Eljilany, I.; Noor, A.; Paravathaneni, M.; Yassine, I.; Lee, S.J.; Othus, M.; Moon, J.; Kirkwood, J.M.; Sondak, V.K.; Ribas, A.; et al. Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review. Cancers 2023, 15, 2561. https://doi.org/10.3390/cancers15092561
Eljilany I, Noor A, Paravathaneni M, Yassine I, Lee SJ, Othus M, Moon J, Kirkwood JM, Sondak VK, Ribas A, et al. Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review. Cancers. 2023; 15(9):2561. https://doi.org/10.3390/cancers15092561
Chicago/Turabian StyleEljilany, Islam, Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J. Lee, Megan Othus, James Moon, John M. Kirkwood, Vernon K. Sondak, Antoni Ribas, and et al. 2023. "Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review" Cancers 15, no. 9: 2561. https://doi.org/10.3390/cancers15092561
APA StyleEljilany, I., Noor, A., Paravathaneni, M., Yassine, I., Lee, S. J., Othus, M., Moon, J., Kirkwood, J. M., Sondak, V. K., Ribas, A., Grossmann, K. F., & Tarhini, A. A. (2023). Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review. Cancers, 15(9), 2561. https://doi.org/10.3390/cancers15092561